SH3 domain and tetratricopeptide repeats 2Genealiases: CMT4C · MNMN
Q-omics provides the consensus-scored SH3TC2 profile across patient tissues and cancer cell-line models. SH3TC2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SH3TC2 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, SH3TC2 RNA expression shows 16,803 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, COAD, and UVM as cancer lineages where SH3TC2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SH3TC2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SH3TC2 survival associations across molecular data types. SH3TC2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SH3TC2 RNA expression–survival associations across cancer types. High SH3TC2 expression shows unfavorable associations in KIRP, LUAD, HNSC, MESO and PAAD, but favorable associations in ESCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SH3TC2 RNA expression.
This table summarizes SH3TC2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SH3TC2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SH3TC2 shows lower tumor expression in BRCA and UCEC and higher tumor expression in COAD, KIRC, KIRP and BLCA. The COAD box plot shows higher SH3TC2 RNA expression in tumor versus normal tissue (log2 FC = +1.562, t-test p < 0.001).
This table shows molecular features associated with SH3TC2 in patient tissues and cancer cell lines. In patient samples, SH3TC2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SH3TC2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BONE.
